A study of ARGX-110 as a monotherapy for the treatment of relapsed/refractory cutaneous T-cell lymphoma (CTCL)

Trial Profile

A study of ARGX-110 as a monotherapy for the treatment of relapsed/refractory cutaneous T-cell lymphoma (CTCL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 May 2017

At a glance

  • Drugs ARGX 110 (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 May 2017 According to an argenx media release, the company expects topline data by the end of 2018.
    • 20 Apr 2017 New trial record
    • 12 Apr 2017 According to an argenx media release, the company expects to report the topline data in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top